This bill extends through FY2026 provisions that establish a period of market exclusivity for certain new drugs with single enantiomers (i.e., one of a pair of molecules that are mirror images of one another).
Actions
Jun 13, 2022
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.